
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. has demonstrated strong financial growth, with Jornay revenue increasing by 28.2% sequentially and achieving $42 million in revenue, surpassing expectations and representing a 19% year-over-year growth. The company has also seen substantial growth in total prescriptions for Jornay, reaching 192,000, which is a 20% increase from the previous year, contributing to a market share rise in the branded long-acting methylphenidate segment to 23.4%. Furthermore, Collegium raised its 2025 revenue guidance parameters, now expecting between $745 million and $760 million, which reflects optimistic projections for continued expansion within both pediatric and adult segments of its product lineup.
Bears say
Collegium Pharmaceutical Inc is currently facing significant financial challenges that contribute to a negative outlook for its stock. Despite achieving an operating cash flow of $78.4 million for the quarter, there are persistent risks, including declining prescription volumes for key products such as Xtampza ER and Belbuca, coupled with the potential threat of generic competition that could adversely impact revenue streams. Additionally, management's plan to decrease net leverage below 1.0x by year-end 2025 is overshadowed by concerns regarding inadequate supply from third parties, as well as unfavorable reimbursement and pricing dynamics that may inhibit profitability and product commercialization.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares